In last trading session, Day One Biopharmaceuticals Inc (NASDAQ:DAWN) saw 1.24 million shares changing hands with its beta currently measuring -1.31. Company’s recent per share price level of $6.16 trading at -$0.03 or -0.48% at ring of the bell on the day assigns it a market valuation of $624.39M. That closing price of DAWN’s stock is at a discount of -178.25% from its 52-week high price of $17.14 and is indicating a premium of 1.14% from its 52-week low price of $6.09.

For Day One Biopharmaceuticals Inc (DAWN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.22. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Day One Biopharmaceuticals Inc (NASDAQ:DAWN) trade information

Upright in the red during last session for losing -0.48%, in the last five days DAWN remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $6.16 price level, adding 12.25% to its value on the day. Day One Biopharmaceuticals Inc’s shares saw a change of -51.38% in year-to-date performance and have moved -8.88% in past 5-day. Day One Biopharmaceuticals Inc (NASDAQ:DAWN) showed a performance of -14.33% in past 30-days.

Wall Street analysts have assigned a consensus price target of 40 to the stock, which implies a rise of 84.6% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 45. It follows that stock’s current price would drop -289.61% in reaching the projected high whereas dropping to the targeted low would mean a loss of -289.61% for stock’s current value.

Day One Biopharmaceuticals Inc (NASDAQ:DAWN)’s Major holders

RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at DAWN for having 7.87 million shares of worth $108.47 million. And as of 2024-06-30, it was holding 9.0354 of the company’s outstanding shares.

The second largest institutional holder is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, which was holding about 6.43 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.3808 of outstanding shares, having a total worth of $88.61 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Securities Fund-Fidelity Small Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 2.24 shares of worth $13.77 million or 2.21% of the total outstanding shares. The later fund manager was in possession of 1.59 shares on Feb 28, 2025, making its stake of worth around $9.8 million in the company or a holder of 1.57% of company’s stock.